Downs, Jenny http://orcid.org/0000-0001-7358-9037
Ludwig, Natasha N. http://orcid.org/0000-0002-8934-7267
Wojnaroski, Mary
Keeley, Jessica http://orcid.org/0000-0001-9613-4713
Schust Myers, Leah
Chapman, Chere A. T. http://orcid.org/0000-0003-2577-390X
Hecker, JayEtta http://orcid.org/0009-0001-2704-5044
Conecker, Gabrielle http://orcid.org/0000-0003-3274-0292
Berg, Anne T. http://orcid.org/0000-0002-0298-5523
Funding for this research was provided by:
DEE-P Connections
FamilieSCN2A Foundation
Stan Perron Charitable Foundation
Article History
Accepted: 10 October 2023
First Online: 8 December 2023
Declarations
:
: JD has consulted for Marinus, Acadia, Orion, Taysha, Neurogene, and AveXis and has been involved in clinical trials with Newron and Anavex; all remuneration has been made to her department. CC is a shareholder & paid employee of Ardea Outcomes and is funded by Pharma, Biotech, non-profit, and academic contracts and grants. ATB received funding from the FamilieSCN2A Foundation, Biomarin Speaker Bureau, and consulting for Biogen and Encoded.
: This study was performed in line with the principles of the Declaration of Helsinki. Ethical approvals were granted by North Star Ethics Review Board (NB200048, exemption determined January 13, 2022; NB200063, approval June 2, 2022 and amendment approved July 1, 2022).
: Informed consent was obtained from all participants included in the study.